GSK Pharma hits 3-month high in weak market; surges 31% in 7 days
The company's consolidated net profit jumped multifold to Rs 230 crore as compared to Rs 46 crore a year ago in the December ...
Daily2d
GSK Nucala application for COPD accepted for review in China
GSK plc has announced that the China National Medical Products Administration has accepted for review the new drug ...
Pharmabiz4d
China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease
China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...
GSK announces CNMPA accepted review the new drug application for Nucala
GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...
GSK celebrates Nucala review in China for form of pulmonary disease
GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...
GlaxoSmithKline share price extends post-Q3 results rally. Jumps 36% in two days
GlaxoSmithKline share price has surged more than 36% in two sessions after the announcement of Q3 results. The stock has ...